natgillin/translations-raw huggingface dataset:
The clinical relevance of the development of anti-rituximab or anti-rHuPH20 antibodies after treatment with MabThera subcutaneous formulation is not known.
Klinični pomen pojava protiteles proti rituksimabu ali protiteles proti rHuPH20 po zdravljenju s podkožno obliko zdravila MabThera ni znan.
The clinical relevance of the haemagglutination inhibition (HI) titre 1:40 in children is unknown.
Klinični pomen hemaglutininskega inhibicijskega (HI) titra  1:40 pri otrocih ni znan.
The clinical relevance of the haemagglutination inhibition (HI) titre 1:40 in children is unknown.
Klinični pomen titra inhibicije hemaglutinacije (HI)  1:40 pri otrocih ni znan.
The clinical relevance of the increase in norbuprenorphine pharmacokinetic parameters has not been established.
farmakokinetičnih parametrov norbuprenofina niso ugotovili.
The clinical relevance of the skin lesions is not known, however clinical correlates to skin lesions in monkeys have not been observed in human clinical trials of saxagliptin.
Klinični pomen kožnih sprememb ni znan, vendar v kliničnih preskušanjih pri človeku niso opazili kliničnih korelatov kožnih sprememb pri opicah.
The clinical relevance of the skin lesions is not known, however clinical correlates to skin lesions in monkeys have not been observed in human clinical trials of saxagliptin.
Klinični pomen kožnih sprememb ni znan, vendar v kliničnih preskušanjih pri človeku niso opazili klinično primerljivih kožnih sprememb pri opicah.
The clinical relevance of the theoretical risk of tumour cell mobilisation is not fully elucidated.
Klinična pomembnost teoretičnega tveganja mobilizacije tumorskih celic še ni v polnosti pojasnjena.
The clinical relevance of these antibodies is not known; nevertheless the pharmacokinetics, efficacy (determined by pathological Complete Response [pCR]) and safety determined by occurrence of administration related reactions (ARRs) of Herceptin intravenous did not appear to be adversely affected by these antibodies.
Klinični pomen pojava protiteles ni znan, niso pa negativno vplivala na farmakokinetiko, učinkovitost (določeno s patološkim popolnim odgovorom [pCR]) in varnost, določeno s pojavom reakcij, povezanih z aplikacijo zdravila Herceptin v intravenski obliki.
The clinical relevance of these differences is unclear, as Synflorix was observed to be effective against IPD caused by serotype 6B in a double- blind, cluster-randomized clinical study (see Table 1).
Klinični pomen teh razlik ni jasen, kajti v dvojno slepi, klastersko randomizirani klinični študiji je bilo cepivo Synflorix učinkovito proti IPB, ki jo je povzročil serotip 6B (glejte preglednico 1).
The clinical relevance of these findings is currently unknown.
Te spremembe niso klinično pomembne.
The clinical relevance of these findings to human fertility is unknown.
Klinična pomembnost teh ugotovitev za plodnost pri človeku ni znana.
The clinical relevance of this
Klinični pomen tega zmanjšanja ni znan, lahko pa zmanjša abakavirjevo učinkovitost.
The clinical relevance of this
Klinični pomen zmanjšanja
The clinical relevance of this
Klinični pomen zmanjšanja lopinavirjeve koncentracije ni raziskan.
The clinical relevance of this
Klinični pomen zmanjšanja sakinavirjeve koncentracije ni raziskan.
The clinical relevance of this effect has not been evaluated.
Klinični pomen tega učinka niso ovrednotili.
The clinical relevance of this finding is uncertain.
Klinična pomembnost je negotova.
The clinical relevance of this interaction for single dose administration of ulipristal acetate as emergency contraception is not known.
Klinični pomen tega medsebojnega delovanja pri uporabi enega odmerka ulipristalacetata kot nujne kontracepcijeni znan.
The clinical relevance of this interaction is uncertain.
Klinični pomen te interakcije ni znan in tako zmanjšajo njegovo klinično učinkovitost.
The clinical relevance of this observation is unknown.
Klinični pomen tega ni znan.
The clinical relevance of this reduced susceptibility is not fully explored.
Klinični pomen te zmanjšane občutljivosti še ni povsem raziskan.
The clinical relevance of this reduced susceptibility is not fully explored.
Klinični pomen te zmanjšanje občutljivosti še ni popolnoma raziskan.
The clinical relevance, including the long-term safety, of sustained very low levels of LDL C (i.e.,
Klinični pomen, vključno z dolgoročno varnostjo, trajno zelo nizkih vrednosti LDL-H (tj.
The clinical response rate was 18.5 %, median time to progression was 2.8 months (CI: 2.1 - 3.3 months) and the median survival time was 9.9 months (CI: 7.8 - 13.1 months).
Klinični delež odgovorov je bil 18,5 %, mediana časa do napredovanja bolezni je bila 2,8 meseca (CI: 2,1 – 3,3 meseca), mediana preživetja pa je bila 9,9 meseca (CI: 7,8 - 13,1 meseca).
The clinical risks associated with over- and under-dosing.
Klinična tveganja, povezana s premajhnim in prevelikim odmerjanjem.
The clinical safety and efficacy of Lucentis in patients with visual impairment due to macular oedema secondary to RVO have been assessed in the randomised, double-masked, controlled studies BRAVO and CRUISE that recruited subjects with BRVO (n=397) and CRVO (n=392), respectively.
Klinično varnost in učinkovitost zdravila Lucentis so pri bolnikih z okvaro vida zaradi makularnega edema pri zapori mrežnične vene ocenjevali v dveh randomiziranih, dvojno slepih, kontroliranih študijah BRAVO in CRUISE, v katere so vključili preiskovance z zaporo veje centralne mrežnične vene (n=397) in preiskovance z zaporo centralne mrežnične vene (n=392).
The clinical safety and efficacy of sunitinib has been studied in the treatment of patients with GIST who were resistant to imatinib (i.e. those who experienced disease progression during or following treatment with imatinib) or intolerant to imatinib (i.e. those who experienced significant toxicity during treatment with imatinib that precluded further treatment), the treatment of patients with MRCC and the treatment of patients with unresectable pNET.
Klinično varnost in učinkovitost sunitiniba so raziskali pri zdravljenju bolnikov z GIST, ki so bili odporni proti imatinibu (tj. jim je bolezen med zdravljenjem z imatinibom ali po njem napredovala) ali imatiniba niso prenašali (tj. so med zdravljenjem z njim imeli pomembne toksične učinke, ki so preprečili nadaljnjo zdravljenje), zdravljenju bolnikov z MRCC in zdravljenju bolnikov s pNET.
The clinical significance
Klinični pomen zmanjšanja
The clinical significance of
Klinični pomen zmanjšanja
The clinical significance of anti-trastuzumab emtansine antibodies is not yet known.
Klinični pomen protiteles proti trastuzumabu emtanzinu še ni znan.
The clinical significance of the decrease in mean plasma CLT, and the associated increase in AUC0-∞ noted in these pharmacokinetic studies of dalbavancin in subjects with severe renal impairment has not been established.
Klinične pomembnosti zmanjšanja plazemskega CLT in povezanega zvišanja AUC0-∞, zabeleženega v teh farmakokinetičnih študijah dalbavancina pri osebah s hudo okvaro ledvic, niso ugotovili.
The clinical significance of the glucose-lowering effect of M1 is unclear.
Klinični pomen vpliva M1 na zniževanje glukoze ni jasen.
The clinical significance of these
Klinični pomen teh sprememb v
The clinical significance of these effects is not known.
Klinični pomen teh učinkov na vrednost AUC etinilestradiola ni znan. etinilestradiol:
The clinical status of the patient and the ADR profile of Zalmoxis should be born in mind when considering the patient’s ability to perform tasks that require judgement, motor or cognitive skills.
Pri tehtanju bolnikove sposobnosti izvajanja nalog, pri katerih so potrebni presoja in motorične ali kognitivne spretnosti, je treba upoštevati klinično stanje bolnika in profil neželenih učinkov zdravila Zalmoxis.
The clinical status of the patient and the adverse event profile of lapatinib should be borne in mind when considering the patient's ability to perform tasks that require judgement, motor or cognitive skills.
Pri presojanju sposobnosti bolnika za opravila, ki zahtevajo presojo in motorične ter kognitivne sposobnosti, je treba upoštevati tako klinično stanje kot profil neželenih učinkov lapatiniba.
The clinical status of the patient and the adverse event profile of Trizivir should be borne in mind when considering the patient’s ability to drive or operate machinery.
Pri presojanju bolnikovih sposobnosti za vožnjo in upravljanje s stroji je potrebno upoštevati tako klinično stanje bolnika kot možne neželene učinke zdravila Trizivir.
The clinical status of the patient and the adverse reaction profile of ambrisentan (such as hypotension, dizziness, asthenia, fatigue) should be borne in mind when considering the patient's ability to perform tasks that require judgement, motor or cognitive skills (see section 4.8).
Pri ocenjevanju bolnikove zmožnosti za izvajanje opravil, ki zahtevajo presojo in motorične ali kognitivne sposobnosti, je treba upoštevati njegovo klinično stanje in profil neželenih učinkov ambrisentana (npr. hipotenzijo, omotico, astenijo in utrujenost (glejte poglavje 4.8).
The clinical status of the patient and the adverse reaction profile of ambrisentan (such as hypotension, dizziness, asthenia, fatigue) should be borne in mind when considering the patient's ability to perform tasks that require judgement, motor or cognitive skills (see section 4.8).
Pri ocenjevanju bolnikove zmožnosti za izvajanje opravil, ki zahtevajo presojo in motorične ali kognitivne sposobnosti, je treba upoštevati njegovo klinično stanje in profil neželenih učinkov ambrisentana, npr. hipotenzijo, omotico, astenijo in utrujenost (glejte poglavje 4.8).
The clinical status of the patient and the adverse reaction profile of eltrombopag, including dizziness and lack of alertness, should be borne in mind when considering the patient’s ability to perform tasks that require judgement, motor and cognitive skills.
Potrebno je upoštevati klinični status bolnika in profil neželenih učinkov eltrombopaga, vključno z omotico in pomanjkanjem pozornosti, ko ocenjujemo bolnikovo sposbnost za izvajanje aktivnosti, ki potrebujejo presojo, motorne in kognitivne spretnosti.
The clinical status of the patient and the adverse reaction profile of Kivexa should be borne in mind when considering the patient’s ability to drive or operate machinery.
Pri presojanju bolnikovih sposobnosti za vožnjo in upravljanje s stroji je potrebno upoštevati tako klinično stanje bolnika kot možne neželene reakcije zdravila Kivexa.
The clinical status of the patient and the adverse reaction profile of macitentan (such as headache, hypotension) should be kept in mind when considering the patient’s ability to drive and use machines.
Pri pretehtanju bolnikove sposobnosti za vožnjo in upravljanje s stroji je treba upoštevati klinični status bolnika in profil neželenih učinkov macitentana (kot so glavobol, hipotenzija).
The clinical status of the patient and the adverse reaction profile of selexipag (such as headache or hypotension) should be kept in mind when considering the patient’s ability to drive and use machines.
Pri presoji bolnikove sposobnosti za vožnjo in upravljanje s stroji je treba upoštevati klinični status bolnika in profil neželenih učinkov seleksipaga (kot sta glavobol, hipotenzija).
The clinical status of the patient and the adverse reaction profile of Triumeq should be borne in mind when considering the patient’s ability to drive or operate machinery.
Pri presojanju bolnikovih sposobnosti za vožnjo in upravljanje s stroji je potrebno upoštevati tako klinično stanje bolnika kot možne neželene učinke zdravila Triumeq.
The clinical status of the patient and the adverse reaction profile should be borne in mind when considering the patient’s ability to perform tasks that require judgement, motor and cognitive skills.
Pri ocenjevanju bolnikove zmožnosti za izvajanje opravil, ki zahtevajo presojo in motorične ali kognitivne sposobnosti, je treba upoštevati njegovo klinično stanje in profil neželenih učinkov zdravila.
The clinical studies have been conducted in a patient population with a mean age > 65 years.
Srednja starost populacije bolnikov v raziskavah je bila > 65 let.
The clinical studies supporting the safety and efficacy of lomitapide in HoFH would have been unlikely to detect this adverse outcome given their size and duration.
Glede na velikost in trajanje kliničnih študij, ki podpirajo varnost in učinkovitost lomitapida pri homozigotni družinski hiperholesterolemiji (HoFH), ni verjetno, da bi ta neželeni učinek zaznali.
The clinical study report (70 patients) should include the following data: Demographic and baseline characteristics, Disease characteristics, Prior anti-cancer therapies, Overall Response Rate (ORR), Clinical Benefit Rate (CBR), Serious Adverse Experiences (SAE)s
Poročilo o klinični študiji (70 bolnikov) mora vključevati naslednje podatke: demografske in izhodiščne značilnosti, značilnosti bolezni, predhodna zdravljenje proti raku, celokupni delež odziva (ORR - Overall Response Rate), delež klinične koristi (CBR - Clinical Benefit Rate), resne neželene učinke (SAE - Serious Adverse Experiences)
The clinical trial data currently available in paediatric patients is too limited to characterise the safety profile of mepolizumab in this population (see section 5.1).
Iz kliničnih preskušanj je o pediatričnih bolnikih trenutno premalo podatkov, da bi lahko opredelili varnostne značilnosti mepolizumaba v tej populaciji (glejte poglavje 5.1).
The clinical trial program in support of this fixed dose combination only compared rosiglitazone and glimepiride to glimepiride monotherapy and not to monotherapy with other sulphonylureas.
Program kliničnega preskušanja za podporo tej kombinaciji fiksnih odmerkov je primerjal le rosiglitazon in glimepirid z monoterapijo z glimepiridom, ne pa z monoterapijo z drugimi sulfonilsečninami.
The clinical trials before marketing authorisation have been performed up to a BMI equal to 40 kg/m2.
Klinična preskušanja, ki so jih opravili pred izdajo dovoljenja za promet, so zajela bolnike z indeksom telesne mase do 40 kg/m2.
The clinical trials before marketing authorization have been performed up to a BMI equal to 40 kg/m2.
Klinična preskušanja, ki so jih opravili pred izdajo dovoljenja za promet, so zajela bolnike z indeksom telesne mase do 40 kg/m2.
The clinical trials of Instanyl were designed to evaluate safety and efficacy in treating breakthrough pain.
Klinična preskušanja z zdravilom Instanyl so bila zasnovana za ovrednotenje varnosti in učinkovitosti pri zdravljenju prebijajoče bolečine.
The clinically important adverse reactions associated with the use of thalidomide in combination with melphalan and prednisone or dexamethasone include: deep vein thrombosis and pulmonary embolism, peripheral neuropathy, severe skin reactions including Stevens Johnson Syndrome and toxic epidermal necrolysis, syncope, bradycardia, and dizziness (see sections 4.2, 4.4 and 4.5).
Klinično pomembni neželeni učinki, povezani z uporabo talidomida v kombinaciji z melfalanom in prednizonom ali deksametazonom, vključujejo: globoko vensko trombozo in pljučno embolijo, periferno nevropatijo, resne kožne reakcije, vključno s sindromom Stevens Johnson in toksično epidermalno nekrolizo, bradikardijo, sinkopo in vrtoglavico (glejte poglavja 4.2, 4.4 in 4.5).
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below.
Klinično pomembni neželeni odzivi, zabeleženi v študijah CAPRIE, CURE, CLARITY in COMMIT so predstavljeni spodaj.
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below.
Klinično pomembni neželeni odzivi, zabeleženi v študijah CAPRIE, CURE, CLARITY, COMMIT in ACTIVE-A so predstavljeni spodaj.
The clinically relevant toxicological effects of these three medicinal products are anaemia, neutropenia and leucopenia.
Klinično pomembni toksikološki učinki teh treh učinkovin so anemija, nevtropenija in levkopenija.
The clock should start from the first Monday after shipment of the first batch of vaccine.
Ura steče prvi ponedeljek po odpremljenju prve serije cepiva.
The clock should start from the first Monday after shipment of the first batch of vaccine.
Čas se začne meriti prvi ponedeljek po dostavi prve serije cepiva.
The clock should start from the first Monday after shipment of the first batch of vaccine.
Čas začne teči prvi ponedeljek po odpremi prve serije cepiva.
The clock will start from the first Monday after shipment of the first batch of vaccine.
Čas bo pričel teči prvi ponedeljek po pošiljki prve serije cepiva.
the clot can cut off the blood supply completely; this can cause a heart attack (myocardial
lahko strdek povsem prekine pretok krvi - posledica je lahko srčni infarkt (miokardni infarkt) ali
The Cmax and area under the plasma concentration-time curve (AUC) increase with dose increase from 0.15 mg/kg to 0.5 mg/kg in a dose- proportional manner.
Cmax in površina pod krivuljo koncentracije v plazmi v odvisnosti od časa (AUC) se z zvečanjem odmerka zvečata sorazmerno odmerku od 0,15 mg/kg do 0,5 mg/kg.
The Cmax and AUC are approximately 40% to 50% higher in females than in males.
Cmax in AUC sta pribliţno 40 % do 50 % večja pri ţenskah kot pri moških.
The Cmax and AUC following a 2- to 10-minute intravenous infusion of 27 mg/m2 was 4,232 ng/mL and 379 ng•hr/mL, respectively.
Po 2- do 10-minutni intravenski infuziji odmerka 27 mg/m2 je bila Cmax 4.232 ng/ml in AUC 379 ng•hr/ml.
The Cmax and AUC of ceftaroline increase approximately in proportion to dose within the single dose range of 50 to 1000 mg.
Cmax in AUC ceftarolina naraščata približno sorazmerno z odmerkom pri enkratnem odmerku v odmernem območju od 50 do 1000 mg.
The Cmax and AUC of ceftolozane/tazobactam increase approximately in proportion to dose within ceftolozane single-dose range of 250 mg to 3 g and tazobactam single-dose range of 500 mg to 1.5 g.
Cmax in AUC ceftolozana/tazobaktama naraščata približno sorazmerno odmerku v razponu enkratnega odmerka ceftolozana od 250 mg do 3 g in v razponu enkratnega odmerka tazobaktama od 500 mg do 1,5 g.
The Cmax and AUC of mirabegron and its metabolites following multiple oral doses in elderly volunteers (≥ 65 years) were similar to those in younger volunteers (18–45 years).
Cmax in AUC mirabegrona in njegovih presnovkov sta bili po večkratnih peroralnih odmerkih pri starejših prostovoljcih (≥ 65 let) podobni kot pri mlajših (18-45 let).
The Cmax and AUC(0–∞) were slightly decreased for ethinyl estradiol (8% and 4%, respectively), and slightly increased for norethindrone (13% and 14 %, respectively).
Cmax in AUC(0–∞) etinilestradiola sta se rahlo zmanjšali (Cmax za 8 % in AUC za 4 %), noretindrona pa rahlo povečali (Cmax za 13 % in AUC za 14 %).
The Cmax and AUCinf of sonidegib in Japanese healthy subjects were 1.56 and 1.68-fold higher, respectively, than those seen in Western healthy subjects for a single dose of 200 mg.
Pri zdravih Japoncih je bila po odmerjanju enkratnega odmerka 200 mg Cmax 1,56-krat višja, AUCinf pa 1,68-krat večja kot pri zdravih osebah iz zahodnega sveta.
The Cmax and time of maximum concentration (tmax) were 206 mcg/ml and 0.32 hr, respectively.
69,1 ml/uro in Vd 3,3L. Cmax je bil 206 mcg/ml in čas največje koncentracije (tmax) 0,32 ur.
The Cmax of rivastigmine was approximately 60 % higher and the AUC of rivastigmine was more than twice as high in subjects with mild to moderate hepatic impairment than in healthy subjects.
Pri osebah z blago do zmerno jetrno okvaro je bila vrednost Cmax rivastigmina približno za 60 % večja, vrednost AUC rivastigmina pa več kot dvakrat večja, kot pri zdravih osebah.
The Cmax of the active metabolite is twice as high following a single 300 mg clopidogrel loading dose as it is after four days of 75 mg maintenance dose.
Cmax aktivnega presnovka je po enem 300 mg začetnem odmerku klopidogrela dvakrat večja kot po štirih dneh uporabe vzdrževalnega odmerka 75 mg.
The Cmax of the active metabolite is twice as high following a single 300-mg clopidogrel loading dose as it is after four days of 75-mg maintenance dose.
Cmax aktivnega presnovka je po 300-mg polnilnem odmerku klopidogrela dvakrat večja kot po štirih dneh uporabe vzdrževalnega odmerka 75 mg.
The Cmax of the active metabolite is twice as high following a single 300-mg clopidogrel loading dose as it is after four days of 75-mg maintenance dose.
Cmax aktivnega presnovka je po enem 300 mg polnilnem odmerku klopidogrela dvakrat večja kot po štirih dneh uporabe vzdrževalnega odmerka 75 mg.
The Cmax of the active metabolite is twice as high following a single 300-mg clopidogrel loading dose as it is after four days of 75-mg maintenance dose.
Cmax aktivnega presnovka je po enem 300-mg polnilnem odmerku klopidogrela dvakrat večja kot po štirih dneh uporabe vzdrževalnega odmerka 75 mg.
The Cmax, AUC(0- 24), and Cmin for these subjects was 6.31 ng/ml, 18.33 ng h/ml, and 0.28 ng/ml, respectively.
Pri teh bolnikih je vrednost Cmax znašala 6,31 ng/ml, vrednost AUC (0-24) 18,33 ng h/ml, vrednost Cmin pa 0,28 ng/ml.
The Cmax, AUC(0- 24), and Cmin for these subjects was 6.31 ng/ml, 18.33 ng·h/ml, and 0.28 ng/ml, respectively.
Pri teh bolnikih je vrednost Cmax znašala 6,31 ng/ml, vrednost AUC (0-24) 18,33 ng h/ml, vrednost Cmin pa 0,28 ng/ml.
The Cmax, tmax, and AUC of plasma erythromycin base were increased 1.6-fold, 1.3-fold, and 1.7-fold, respectively.
Cmax, tmax in AUC eritromicina v plazmi v izhodišču se posledično zvečajo za 1,6-krat, 1,3-krat in 1,7-krat.
The co-administration of 200 mg ciclosporin (a BCRP inhibitor) decreased the Cmax and the AUCinf of eltrombopag by 25% and 18%, respectively.
Sočasno odmerjanje 200 mg ciklosporina (zaviralca proteina BCRP) je znižalo Cmax eltrombopaga za 25 % in zmanjšalo njegovo AUCinf za 18 %.
The co-administration of 600 mg ciclosporin decreased the Cmax and the AUCinf of eltrombopag by 39% and 24%, respectively.
Sočasno odmerjanje 600 mg ciklosporina je znižalo Cmax eltrombopaga za 39 % in zmanjšalo njegovo AUCinf za 24 %.
The co-administration of beta-blockers or calcium antagonists with depressant effect on sinus and atrio-ventricular node should be undertaken with caution.
Previdnost je potrebna v primeru sočasne uporabe zaviralcev adrenergičnih receptorjev beta ali kalcijevih antagonistov z zaviralnim delovanjem na sinusni in atrioventrikularni vozel.
The co-administration of Descovy is not recommended with certain anticonvulsants (e.g., carbamazepine, oxcarbazepine, phenobarbital and phenytoin), antimycobacterials (e.g., rifampicin, rifabutin, rifapentine), boceprevir, telaprevir, St. John’s wort and HIV protease inhibitors (PIs) other than atazanavir, lopinavir and darunavir (see section 4.5).
Sočasna uporaba zdravila Descovy z nekaterimi antikonvulzivi (npr. karbamazepinom, okskarbazepinom, fenobarbitalom in fenitoinom), zdravili za zdravljenje okužb z mikobakterijami (npr. rifampicinom, rifabutinom, rifapentinom), boceprevirjem, telaprevirjem, šentjanževko in zaviralci proteaze [protease inhibitors, PI] HIV, razen z atazanavirjem, lopinavirjem in darunavirjem (glejte poglavje 4.5) ni priporočljiva.
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner.
Sočasno jemanje doksazocina (4 in 8 mg dnevno) in tadalafila (5 mg dnevno in 20 mg v enkratnem odmerku) znatno poveča učinek zniževanja krvnega tlaka tega zaviralca alfa.
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner.
Sočasno jemanje doksazosina (4 in 8 mg dnevno) in tadalafila (dnevni odmerek 5 mg in enkratni odmerek 20 mg) signifikantno okrepi hipotenzivni učinek zaviralca adrenergičnih receptorjev alfa.